Reviva Pharmaceuticals Holdings (RVPH) risk factors, FY2025 10-K

Risks Related to Our Business, Financial Position and Capital Requirements

1. 01We have never generated any product revenues
2. 02Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products
3. 03maintain, expand and protect our intellectual property portfolio
4. 04We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability25% rewritten
5. 05pre-clinical studies and clinical studies for RP1208 for the treatment of depression and obesity51% rewritten
6. 06Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern
7. 07We are heavily dependent on the success of brilaroxazine, our only advanced product candidate, which is still under clinical development, and if brilaroxazine does not receive regulatory approval or is not successfully commercialized, our business will be harmed
8. 08We face risks related to health epidemics and outbreaks, including any future health crises, pandemics or other widespread health crises or similar events, which could adversely impact our business, including our clinical trials51% rewritten
9. 09the initiation, progress, timing and results of our commercialization of brilaroxazine, RP1208 or any future product candidates, if approved for commercial sale
10. 10Raising additional funds by issuing securities may cause dilution to existing stockholders, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights
11. 11We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations
12. 12If we seek to enter into strategic alliances for the development of brilaroxazine or RP1208 but fail to enter into and maintain successful strategic alliances, our development costs may increase and our ability to develop brilaroxazine or RP1208 may be significantly delayed28% rewritten
13. 13To the extent we are able to enter into collaborative arrangements or strategic alliances, we will be exposed to risks related to those collaborations and alliances
14. 14Our business and operations would suffer in the event our computer systems and networks fail
15. 15Computer system interruptions, cyber-attacks or security breaches could significantly disrupt our product development programs and our ability to operate our business
16. 16Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop
17. 17If the interpretations, estimates or judgments we use to prepare our financial statements prove to be incorrect, we may be required to restate our financial results, which could have a number of material adverse effects on us
18. 18Unfavorable global economic conditions and adverse developments with respect to financial institutions and associated liquidity risk could adversely affect our business, financial condition and stock price

Risks Related to Development, Regulatory Approval and Commercialization

1. 19Drug development is a very expensive, lengthy and uncertain process
2. 20Clinical trials are very expensive, time-consuming, difficult to design and implement and involve an uncertain outcome
3. 21In addition, our management has limited prior experience in managing and completing late-stage clinical trials, and may not be able to successfully design and implement these trials or respond to adverse factors that may arise in the course of conducting these trials
4. 22The results of our clinical trials may not support our brilaroxazine, RP1208 and any future product candidate claims
5. 23Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside of our control
6. 24The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges
7. 25We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively
8. 26Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors
9. 27The availability of our competitors’ products could limit the demand, and the price we are able to charge, for any product candidate it develops. The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects
10. 28If we are not able to obtain required regulatory approvals, we will not be able to commercialize brilaroxazine, RP1208 or any other product candidates, and our ability to generate revenue will be materially impaired
11. 29Prior to submitting a new drug application (“NDA”) to the FDA, a marketing authorization application, or MAA, to the EMA, or an equivalent application to other foreign regulatory authorities for approval of brilaroxazine, we will need to complete our clinical studies including the RECOVER-2 Trial
12. 30We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates
13. 31Brilaroxazine, RP1208 and any future product candidate may cause adverse effects or have other properties that could delay or prevent its regulatory approval or limit the scope of any approved label or market acceptance
14. 32our reputation may suffer
15. 33The results of pre-clinical testing are not necessarily predictive of future results, and RP1208 and other product candidates may not have favorable results in our planned clinical trials
16. 34Changes in product candidate manufacturing or formulation may result in additional costs, delay or non-approval
17. 35Any breakthrough therapy designation granted by the FDA for our product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidate will receive marketing approval
18. 36Even if we obtain FDA approval for brilaroxazine, RP1208 or any future product candidate in the United States, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential
19. 37Even if we obtain regulatory approval for brilaroxazine, RP1208 or any future product candidate, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties
20. 38injunctions or the imposition of civil or criminal penalties
21. 39Even if brilaroxazine, RP1208 or any future product candidate receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success
22. 40If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third-parties, we may not be successful in commercializing brilaroxazine, RP1208 or any future product candidate, if approved
23. 41unforeseen costs and expenses associated with creating an independent sales and marketing organization
24. 42If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business
25. 43business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires
26. 44Our subsidiary may not be in compliance with the laws of foreign countries, and it may face penalties and fines imposed by the Indian government
27. 45Our current and future relationships with foreign actors such as, health care and administrative professionals at foreign state owned hospitals or foreign government healthcare regulators will be subject to applicable anti-corruption laws regulatory laws, which could expose us to penalties
28. 46Our current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties
29. 47Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize brilaroxazine, RP1208 or any future product candidate and affect the prices we may obtain
30. 48Coverage and adequate reimbursement may not be available for brilaroxazine, RP1208 or any future product candidate, which could make it difficult for us to sell our products profitably

Risks Related to Our Dependence on Third Parties

1. 49We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of brilaroxazine, RP1208 and any future product candidate
2. 50failure to deliver our products under specified storage conditions and in a timely manner
3. 51We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance
4. 52Changes in the U.S. political and regulatory environment could affect availability of government funding that we or our third-party collaborators may rely on, which could negatively impact the development of our product candidates

Risks Related to Our Intellectual Property

1. 53If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets
2. 54Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
3. 55Third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, may delay or prevent the development and commercialization of brilaroxazine, RP1208 and any future product candidate73% rewritten
4. 56We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful
5. 57We may not be able to protect our intellectual property rights throughout the world, which could impair our business
6. 58Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks Related to Our Securities

1. 59We are currently listed on The Nasdaq Capital Market. If we fail to regain and maintain compliance with the requirements of The Nasdaq Capital Market for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted95% rewritten
2. 60An active trading market for our common stock may not be sustained63% rewritten
3. 61Our officers, directors, and principal stockholders exercise significant voting power and influence with respect to matters impacting our Company, including with respect to the outcome of matters requiring stockholder approval29% rewritten
4. 62A sale of a substantial number of shares of our common stock or warrants in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well
5. 63If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline25% rewritten
6. 64The price of our common stock may be volatile, which could subject us to securities class action litigation and our stockholders could incur substantial losses
7. 65general economic, market or political conditions in the United States or elsewhere
8. 66proposals for legislation that would place restrictions on the price of pharmaceutical products
9. 67Certain of our warrants are accounted for as liabilities and the changes in value of such warrants could have a material effect on our financial results64% rewritten
10. 68We do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, any gains from an investment in our common stock will likely depend on appreciation in the price of our common stock25% rewritten
11. 69Upon our dissolution, the stockholders may not recoup all or any portion of their investment
12. 70Our certificate of incorporation, as amended and restated, allows for our board of directors to create new series of preferred stock without further approval by the stockholders, which could adversely affect the rights of the holders of our common stock
13. 71Delaware law and our certificate of incorporation, as amended and restated, and our bylaws contain certain provisions, including anti-takeover provisions that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable
14. 72These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our board of directors or management. In addition, as a Delaware corporation, we will generally be subject to provisions of Delaware law, including Section 203 of the DGCL